A disturbing revelation has emerged from Noida's district hospital, where a batch of substandard antibiotics was distributed to patients over the past one and a half months. The affected medication, amoxicillin and potassium clavulanate IP 625 mg, was supplied by an Indore-based pharmaceutical company.
Quality Testing Reveals Shortcomings:
Routine testing conducted by the central lab in Lucknow uncovered the substandard quality of the antibiotics. While the amoxicillin content met the required 90% standard, the potassium clavulanate content fell short, measuring only 81% instead of the required 90%. This reduced potency compromises the drug's effectiveness.
Thousands of Patients Affected:
Approximately 8,000 tablets of the substandard antibiotics were distributed to patients before the issue was detected. Fortunately, officials confirm that the medication poses no immediate harm to patients. However, its reduced effectiveness raises concerns about the treatment's efficacy.
Prompt Action Taken:
Upon receiving the test results, the Food Safety and Drug Administration (FSDA) swiftly seized the remaining stock and halted further distribution. The hospital authorities have also initiated an investigation and returned the unused portion of the stock to the supplier.
Official Response:
"We take the quality of medications seriously," said Dr. Renu Agarwal, Chief Medical Superintendent (CMS). "We have ceased distribution and returned the remaining stock to ensure our patients receive only high-quality medications."
Regulatory Action:
The FSDA has issued a notice to the hospital's store in-charge and is taking action against the supplier. "We will investigate and take further legal action," said Jai Singh, Drug Inspector.
Concerns Raised:
This incident raises concerns about the quality control measures in place at pharmaceutical companies and hospitals. It highlights the need for stringent testing and monitoring to ensure patients receive effective and safe medications.
Key Takeaways:
1. Substandard antibiotics distributed at Noida hospital.
2. 8,000 tablets affected.
3. Reduced potency compromises effectiveness.
4. No immediate harm to patients.
5. Prompt action taken by FSDA and hospital authorities.
(Input from various sources)
(Rehash/Vaishnavi Dalvi/MSM)
